Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HFB301001 |
| Synonyms | |
| Therapy Description |
HFB301001 is an agonistic antibody targeting OX40, which potentially enhances effector T cells and decreases regulatory T cells, leading to antitumor activity (Ann Oncol 2022, Vol 33, Suppl 7, Abstract # S899). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HFB301001 | HFB-301001|HFB 301001 | OX40 Antibody 15 | HFB301001 is an agonistic antibody targeting OX40, which potentially enhances effector T cells and decreases regulatory T cells, leading to antitumor activity (Ann Oncol 2022, Vol 33, Suppl 7, Abstract # S899). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05229601 | Phase I | HFB301001 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Terminated | USA | ESP | 0 |